Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Switzerland Tech Review.
Press releases published on July 8, 2025
Karger Joins NICE Knowledge Resources Framework to Provide Peer-Reviewed Medical Content to NHS Libraries
EIN Presswire
·
July 8, 2025
Karger Publishers’ eBook and eJournal collections are now available for NHS Libraries to buy via the National Institute of Health and Care Excellent Framework BASEL, SWITZERLAND, July 8, 2025 /EINPresswire.com/ -- In meeting the stringent criteria of …
Bright Pattern and AvanteNow Partner to Deliver IT Service Management with AI-Powered Contact Center Capabilities
EIN Presswire
·
July 8, 2025
SAN FRANCISCO, CA, UNITED STATES, July 8, 2025 /EINPresswire.com/ -- Bright Pattern, a global leader in AI-powered cloud-based contact center solutions, and AvanteNow, a renowned IT service specialist, have announced a new partnership. This collaboration …
Azilen and Augmenticon Announce Strategic Partnership to Transform APQRs with AI
EIN Presswire
·
July 8, 2025
Azilen and Augmenticon AG are co-developing an AI-powered solution to transform the approach of Annual and Product Quality Reviews in the pharmaceutical. ZURICH, SWITZERLAND, July 8, 2025 /EINPresswire.com/ -- Azilen Technologies and Augmenticon AG have …
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere Entwicklung der neuen Antipilzmittel Fosmanogepix und BAL2062
GlobeNewswire
·
July 8, 2025
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 08. Juli 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren …
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
GlobeNewswire
·
July 8, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal …